Ann Thorac Surg 2007;83:160
© 2007 The Society of Thoracic Surgeons
Original Articles: Cardiovascular
Invited commentary
Michael E. Jessen, MD
Department of Cardiovascular & Thoracic Surgery, University of Texas Southwestern Medical Ctr, 5323 Harry Hines Blvd Dallas, TX 75390-8879
(Email: michael.jessen@utsouthwestern.edu).
| The first 20% of the full text of this article appears below. |
Although infrequent, the occurrence of acute lung injury (ALI) after cardiopulmonary bypass (CPB) remains a serious problem. In this report, Wakayama and colleagues [1] describe the effect of Sivelestat (Ono Pharmaceutical Co. Ltd, Osaka, Japan), a neutrophil elastase inhibitor, on the development of ALI after exposure to lipopolysaccharide (LPS) and CPB. In a rabbit model, the combination of LPS and CPB led to an elevation in elastase activity and interleukin-8 levels, an accumulation of . . . [Full Text of this Article]
Related Article
-
Neutrophil Elastase Inhibitor, Sivelestat, Attenuates Acute Lung Injury After Cardiopulmonary Bypass in the Rabbit Endotoxemia Model
- Fuminori Wakayama, Ikuo Fukuda, Yasuyuki Suzuki, and Norihiro Kondo
Ann. Thorac. Surg. 2007 83: 153-160.
[Abstract]
[Full Text]
[PDF]
Copyright © 2007 by The Society of Thoracic Surgeons.